JP2007503847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007503847A5 JP2007503847A5 JP2006532294A JP2006532294A JP2007503847A5 JP 2007503847 A5 JP2007503847 A5 JP 2007503847A5 JP 2006532294 A JP2006532294 A JP 2006532294A JP 2006532294 A JP2006532294 A JP 2006532294A JP 2007503847 A5 JP2007503847 A5 JP 2007503847A5
- Authority
- JP
- Japan
- Prior art keywords
- poxvirus
- insertion site
- open reading
- foreign gene
- reading frames
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000003780 insertion Methods 0.000 claims 4
- 230000037431 insertion Effects 0.000 claims 4
- 108700026244 Open Reading Frames Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 108091029795 Intergenic region Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44859103P | 2003-02-20 | 2003-02-20 | |
| US60/448,591 | 2003-02-20 | ||
| PCT/US2004/005077 WO2005048957A2 (en) | 2003-02-20 | 2004-02-20 | Novel insertion sites in pox vectors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010120319A Division JP5053420B2 (ja) | 2003-02-20 | 2010-05-26 | ポックスベクターにおける新規の挿入部位 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007503847A JP2007503847A (ja) | 2007-03-01 |
| JP2007503847A5 true JP2007503847A5 (https=) | 2010-07-15 |
| JP5052893B2 JP5052893B2 (ja) | 2012-10-17 |
Family
ID=34619255
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006532294A Expired - Lifetime JP5052893B2 (ja) | 2003-02-20 | 2004-02-20 | ポックスベクターにおける新規の挿入部位 |
| JP2010120319A Expired - Lifetime JP5053420B2 (ja) | 2003-02-20 | 2010-05-26 | ポックスベクターにおける新規の挿入部位 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010120319A Expired - Lifetime JP5053420B2 (ja) | 2003-02-20 | 2010-05-26 | ポックスベクターにおける新規の挿入部位 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7638134B2 (https=) |
| EP (2) | EP2363493B1 (https=) |
| JP (2) | JP5052893B2 (https=) |
| AU (1) | AU2004291024B2 (https=) |
| CA (1) | CA2515890C (https=) |
| WO (1) | WO2005048957A2 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2062023T4 (en) † | 2006-08-25 | 2017-02-20 | The Government Of The Us Secretary Dept Of Health And Human Services | INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS |
| EP2097517B1 (en) | 2006-10-16 | 2014-06-04 | Genelux Corporation | Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody |
| JP5721428B2 (ja) * | 2007-04-27 | 2015-05-20 | バヴァリアン・ノルディック・アクティーゼルスカブ | マクロファージ−コロニー刺激因子（ｍ−ｃｓｆ）による樹状細胞発生の誘導 |
| US8268327B2 (en) * | 2007-04-27 | 2012-09-18 | Bavarian Nordic A/S | Immediate protection against pathogens via MVA |
| AU2009212787B2 (en) * | 2007-04-27 | 2015-03-26 | Bavarian Nordic A/S | Induction of dendritic cell development with macrophage-colony stimulating factor (M-CSF) |
| US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| GB201006405D0 (en) | 2010-04-16 | 2010-06-02 | Isis Innovation | Poxvirus expression system |
| EP2800762B1 (en) | 2012-01-03 | 2018-01-03 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Native and agonist ctl epitopes of the muc1 tumor antigen |
| HK1209140A1 (en) | 2012-07-19 | 2016-03-24 | Zoetis Services Llc | Bovine influenza c virus compositions |
| WO2014018724A1 (en) | 2012-07-27 | 2014-01-30 | Zoetis Llc | Tick toxin compositions |
| WO2014048500A1 (en) * | 2012-09-28 | 2014-04-03 | Probiogen Ag | Novel mva virus and uses thereof |
| WO2015061416A2 (en) | 2013-10-23 | 2015-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use |
| US11701418B2 (en) | 2015-01-12 | 2023-07-18 | Geovax, Inc. | Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40) |
| KR20160140075A (ko) * | 2015-05-29 | 2016-12-07 | 코오롱생명과학 주식회사 | 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터 |
| ES2901468T3 (es) * | 2015-07-31 | 2022-03-22 | Bavarian Nordic As | Promotores para mejorar la expresión en poxvirus |
| EP4137150A1 (en) | 2015-08-03 | 2023-02-22 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use |
| CA2995101A1 (en) | 2015-08-14 | 2017-02-23 | Zoetis Services Llc | Mycoplasma bovis compositions |
| WO2017120577A1 (en) | 2016-01-08 | 2017-07-13 | Geovax Inc. | Compositions and methods for generating an immune response to a tumor associated antigen |
| WO2017136419A1 (en) | 2016-02-03 | 2017-08-10 | Geovax Inc. | Compositions and methods for generating an immune response to a flavivirus |
| EP3535284B1 (en) | 2016-11-07 | 2021-04-21 | The United States of America as represented by The Secretary Department of Health and Human Services | Development of agonist epitopes of the human papillomavirus |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| EP3880694A1 (en) | 2018-11-14 | 2021-09-22 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Tp5, a peptide inhibitor of aberrant and hyperactive cdk5/p25 as treatment for cancer |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| WO2021150713A2 (en) | 2020-01-21 | 2021-07-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human immunogenic epitopes of h, k, and e human endogenous retroviruses (hervs) |
| US20230287067A1 (en) | 2020-01-21 | 2023-09-14 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Human immunogenic epitopes of hemo and hhla2 human endogenous retroviruses (hervs) |
| US20230097513A1 (en) * | 2020-02-03 | 2023-03-30 | City Of Hope | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof |
| EP4103231A4 (en) | 2020-02-14 | 2024-03-27 | Geovax, Inc. | VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2 |
| TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| WO2021209897A1 (en) | 2020-04-13 | 2021-10-21 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
| CA3177517A1 (en) | 2020-05-06 | 2021-11-11 | Ernest S. Smith | Integral membrane protein display on poxvirus extracellular enveloped virions |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| US20230035403A1 (en) | 2020-07-06 | 2023-02-02 | Janssen Biotech, Inc. | Method For Determining Responsiveness To Prostate Cancer Treatment |
| US20230024133A1 (en) | 2020-07-06 | 2023-01-26 | Janssen Biotech, Inc. | Prostate Neoantigens And Their Uses |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| IL318055A (en) | 2022-07-08 | 2025-02-01 | Viromissile Inc | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364773A (en) * | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US4514506A (en) | 1982-02-23 | 1985-04-30 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens |
| CA1340203C (en) | 1987-09-16 | 1998-12-15 | Noboru Yanagida | Recombinant apivoxvirus |
| FR2632863B2 (fr) * | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
| CA1341245C (en) * | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US5093258A (en) | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
| BE1004877A3 (fr) * | 1991-05-27 | 1993-02-16 | Solvay | Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus. |
| DK0538496T3 (da) * | 1991-08-26 | 2004-02-23 | Baxter Healthcare Sa | Rekombinant fjerkrækoppevirus med intakt FPV tk-gen |
| US5445953A (en) * | 1991-08-26 | 1995-08-29 | Immuno Aktiengesellschaft | Direct molecular cloning of a modified poxvirus genome |
| AU687010B2 (en) | 1992-07-17 | 1998-02-19 | Dana-Farber Cancer Institute | Method of intracellular binding of target molecules |
| US5851829A (en) | 1993-07-16 | 1998-12-22 | Dana-Farber Cancer Institute | Method of intracellular binding of target molecules |
| US5656465A (en) | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
| US6045802A (en) | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US5990091A (en) * | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| AUPP380598A0 (en) * | 1998-05-29 | 1998-06-25 | Commonwealth Scientific And Industrial Research Organisation | Genetically manipulated entomopoxvirus |
| JP5639736B2 (ja) * | 1999-05-28 | 2014-12-10 | ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ ＭｕｅｎｃｈｅｎＤｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） | ポックスウイルスゲノムへの異種遺伝子の組込みのためのベクター |
| DK1263936T3 (da) | 2000-03-14 | 2006-02-13 | Bavarian Nordic As | andret stamme af den modificerede Vacciniavirus Ankara (MVA) |
| CU23235A1 (es) * | 2001-02-28 | 2007-09-26 | Ct Ingenieria Genetica Biotech | POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA |
| ATE315660T1 (de) * | 2002-05-16 | 2006-02-15 | Bavarian Nordic As | Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva) |
| WO2004098534A2 (en) | 2003-02-24 | 2004-11-18 | Therion Biologics Corporation | Methods for delivering angiogenic modulators using pox viruses |
-
2004
- 2004-02-20 EP EP11158563A patent/EP2363493B1/en not_active Expired - Lifetime
- 2004-02-20 JP JP2006532294A patent/JP5052893B2/ja not_active Expired - Lifetime
- 2004-02-20 US US10/543,944 patent/US7638134B2/en not_active Expired - Lifetime
- 2004-02-20 WO PCT/US2004/005077 patent/WO2005048957A2/en not_active Ceased
- 2004-02-20 CA CA2515890A patent/CA2515890C/en not_active Expired - Lifetime
- 2004-02-20 EP EP04817689A patent/EP1601333B1/en not_active Expired - Lifetime
- 2004-02-20 AU AU2004291024A patent/AU2004291024B2/en not_active Expired
-
2009
- 2009-12-16 US US12/639,781 patent/US20100136056A1/en not_active Abandoned
-
2010
- 2010-05-26 JP JP2010120319A patent/JP5053420B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007503847A5 (https=) | ||
| DK1784419T3 (da) | Domæner og epitoper på meningococprotein NMB 1870 | |
| DK1701968T3 (da) | Immunogene peptid-bærer-konjugater og fremgangsmåder til deres fremstilling | |
| EP1769050A4 (en) | EFFICIENT GREEN-EMITTING FLUORES AND COMBINATIONS WITH REDEQUIPPING INFLUENCES | |
| SI2019965T1 (sl) | Diferencialna diagnoza med pljučno boleznijo in boleznijo srca in ožilja | |
| JP2011505180A5 (https=) | ||
| DK1663291T3 (da) | Rekombinante lubricinmolekyler og anvendelser deraf | |
| CA122731S (en) | Golf practice mat | |
| IL165052A0 (en) | Medium for contrast enhancement or convenience forultrasonic, endoscopic and other medical examinat ions | |
| HUS1500059I1 (hu) | A HPV16 és HPV18 és a HPV 31, 45 vagy 52 közül legalább egy másik HPV típus elleni vakcina | |
| DE602005012786D1 (de) | Ventil in Schirmform | |
| NO20053947D0 (no) | Forbedrede antitumorale behandlinger. | |
| EP1911388A4 (en) | ENDOSCOPE AND ENDOSCOPE INTRODUCTION SECTION | |
| DE602004032358D1 (de) | Videospielprogramm, videospielvorrichtung und videospielverfahren | |
| ATE549464T1 (de) | Schachtoberteil | |
| IL179138A0 (en) | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31,45, or 52 | |
| ITBO20030698A1 (it) | Infibulo per il collo del femore e strumentazione per il suo inserimento. | |
| PL376122A1 (pl) | Sposób wytwarzania rekombinowanej szczepionki przeciwko krwotocznej chorobie królików, szczepionka oraz zastosowanie antygenu rekombinowanego białka do wytwarzania szczepionki | |
| ES1058795Y (es) | Suela con plantilla incorporada y ventilacion inferior obturable. | |
| EP1927189A4 (en) | INSERTING AND RECALLING IDENTIFYING ARTIFACTS IN TRANSFERRED LOSSES AND LOSS-FREE DATA | |
| CN300730441S (zh) | 充气水池(51102) | |
| CN300895667S (zh) | 电脑台(ct-2411) | |
| Kumar et al. | Babesiosis in donkeys: an update. | |
| DE602004023635D1 (de) | Angiogenesemodelle, wobei nestin-exprimierende stammzellen für das imaging von in bildung begriffenen blutgefässen verwendet werden | |
| EP1594507A4 (en) | NEW COMBINATIONS OF MEDICINES AGAINST HERPES |